Breakthrough Drug DT-109 Reverses Severe Fatty Liver Disease by Healing the Gut

New Study Shows Experimental Drug Targets Gut-Liver Connection to Treat MASH

An experimental drug developed at Michigan Medicine has shown remarkable results in reversing severe fatty liver disease by restoring gut health, offering new hope for millions of people living with this increasingly common condition.

The investigational compound, known as DT-109, is a glycine-based tripeptide that reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal studies by interrupting a harmful biological process linking the gut and liver. The findings were published in The Journal of Clinical Investigation and represent a significant step forward in the search for effective MASH treatments.

What Is MASH and Why Does It Matter?

MASH is a serious, progressive form of fatty liver disease that affects approximately 7% of the global population. It occurs when fat builds up in the liver, causing inflammation and cellular damage. Unlike simple fatty liver, MASH can progress to:

• Cirrhosis – severe scarring of the liver that impairs its function
• Liver cancer – one of the fastest-rising cancers worldwide
• Liver failure – a life-threatening condition requiring transplantation

Despite its prevalence and serious consequences, effective treatment options for MASH remain extremely limited. No FDA-approved medications specifically target the underlying disease mechanisms, leaving diet and lifestyle changes as the primary management strategies.

How DT-109 Works: The Gut-Liver Connection

What makes DT-109 particularly exciting is its unique mechanism of action. Rather than targeting the liver directly, the drug works by restoring health in the gastrointestinal tract.

“We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression,” said Eugene Chen, M.D., Ph.D., senior author of the study and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School.

The research team identified a major contributor to MASH: an overgrowth of the bacterium Clostridium perfringens, which generates ammonia inside the gut. High ammonia levels damage the lining of the digestive tract, weakening the intestinal barrier.

Once that protective barrier is compromised, harmful microbial products can enter the bloodstream, reach the liver, and trigger inflammatory immune responses, including excessive activation of CD8+ T cells. DT-109 disrupts this entire chain of events.

Key Findings from the Study

The research, conducted in both mice and nonhuman primates, yielded several important results:

• Reduced Clostridium perfringens levels – The drug suppressed the harmful bacterial overgrowth in the gut
• Lower ammonia production – Intestinal ammonia levels dropped significantly
• Strengthened intestinal barrier – The gut lining became more resilient, preventing harmful substances from leaking into the bloodstream
• Reduced liver inflammation – In nonhuman primates, DT-109 decreased inflammation and significantly improved MASH severity

The results in nonhuman primates were especially encouraging because their liver biology and gut microbiota more closely resemble those of humans.

Potential Benefits Beyond Fatty Liver Disease

DT-109 may have applications beyond treating MASH. Previous studies have shown the compound can also:

• Reduce the formation of atherosclerosis plaques
• Prevent vascular calcification in nonhuman primates

These findings suggest DT-109 could eventually become a treatment for cardiovascular disease as well. Because breakdown of the intestinal barrier has also been linked to several digestive disorders, researchers believe DT-109 could be explored as a treatment for conditions such as inflammatory bowel disease (IBD).

“What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health — of course we are excited about these developments,” said Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine.

What This Means for Patients

For the millions of people living with MASH or at risk of developing it, this research represents genuine hope. The compound has been patented by the University of Michigan and licensed to Diapin Therapeutics, which is continuing to develop DT-109.

Future research will focus on additional testing needed to move DT-109 into clinical trials and evaluate its safety and effectiveness in people. The fact that DT-109 is a glycine-based tripeptide — a type of amino acid compound — may also simplify the regulatory pathway.

Frequently Asked Questions About MASH and DT-109

What is the difference between fatty liver and MASH?

Simple fatty liver (steatosis) involves fat accumulation in the liver without significant inflammation or damage. MASH (metabolic dysfunction-associated steatohepatitis) is a more severe form that includes liver inflammation and cell damage, putting patients at higher risk of cirrhosis and liver cancer.

Who is at risk for MASH?

Risk factors include obesity, type 2 diabetes, insulin resistance, high cholesterol, metabolic syndrome, and rapid weight loss. MASH is increasingly common as global obesity rates continue to rise.

How is MASH currently treated?

Current treatment primarily focuses on lifestyle modifications including weight loss, dietary changes, regular exercise, and management of associated conditions like diabetes and high cholesterol. There are currently no FDA-approved medications specifically for MASH.

When will DT-109 be available for humans?

DT-109 is still in the preclinical stage. Human clinical trials will be needed to establish safety and effectiveness. The timeline depends on trial results, regulatory approvals, and additional funding for development.

Can diet and lifestyle changes reverse fatty liver disease?

Yes, in many cases. Studies show that losing 7-10% of body weight through diet and exercise can significantly reduce liver fat and inflammation. A Mediterranean-style diet and regular physical activity remain the first-line recommendations for fatty liver management.

Is fatty liver disease reversible?

In its early stages, fatty liver disease is often reversible with lifestyle changes. However, once significant fibrosis or cirrhosis develops, the damage may be permanent. This is why early detection and intervention are critical.

The Bottom Line

The discovery of DT-109’s mechanism represents a paradigm shift in how researchers think about fatty liver disease. By targeting the gut-liver axis — the bidirectional communication between the digestive system and the liver — scientists have opened an entirely new avenue for treating a condition that has frustrated clinicians for decades.

“This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat,” said Dr. Tapper.

As research progresses, DT-109 may eventually join a growing arsenal of treatments for metabolic diseases — and it all starts with healing the gut.